What Is Rifaximin?

This product is a rifamycin derivative and is the first non-aminoglycoside enteric antibiotic. This product has a strong effect and a broad antibacterial spectrum. This product is for Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus faecium in Gram-positive aerobic bacteria; Salmonella, Escherichia coli, Shigella, Yersinia enterocolitica, cocci; Bacteroides in Gram-negative anaerobic bacteria are highly active.

Drug Name: Rifaximin tablets
Foreign name: Rifaximin

Whether prescription drugs: prescription
Main indications: Gram-positive and negative

About Rifaximin

1. Drug name

Chinese Common Name: Rifaximin Tablets

English name: Rifaximin

Phonetic script (Hanyu Pinyin): Lifuximingpian

Chemical name: 4-deoxy-4'-methylpyrido [1 ', 2'-1,2] imidazo [5,4-C] rifamycin SV

Manufacturers' Codes: L-105; L-105SV; a-0817185

Structural formula: (picture)

Percent Composition: C 65.72%, H 6.54%, N 5.35%, O 22.39%

Molecular formula: C43H51N3O11

Molecular weight: 785.88.

CAS Registry Number: 80621-81-4

Properties: This product is orange-red powder, soluble in ethanol, ethyl acetate, chloroform and toluene, but insoluble in water. M. P. 200-205'C.

Rifaximin Pharmacology

This product does not require the use of intestinal antispasmodics (such as loperamide), nor does it require intestinal adsorption drugs (such as white clay, pectin, etc.).

This product works quickly, no more diarrhea after 2 days, abdominal cramping pain, headache and nausea and vomiting symptoms disappear quickly.

This product is not absorbed and has a very high concentration in the intestine. It does not exist in other organs.

The advantages of this product over neomycin, streptomycin and other aminoglycoside antibiotics are as follows: this product does not damage hearing function; it does not cause renal insufficiency; normal parasitic flora, especially intestinal non-pathogenic The bacteria E. coli quickly re-localized in the intestine and avoided repeated infections; inflammation of the intestinal mucosa tended to disappear.

Rifaximin indications

Gram positive and negative. Acute and chronic intestinal infections caused by aerobic and anaerobic bacteria; diarrhea syndrome;

Diarrhea due to changes in intestinal flora (intestinal colitis, antibiotic-induced enterocolitis, traveler's diarrhea); preoperative and postoperative intestinal prophylaxis; excessive blood ammonia, portal venous encephalitis, and liver confusing.

/ Rifaximin dosage form / specification

1. Tablet: 200mg;

2. Powder for oral suspension: Each spoon (5ml) contains 100mg.

Willinin (rifaximin dry suspension) instruction manual

Drug Name

Common name: Rifaximin dry suspension

Product Name: Willining

English name: Rifaximin For Suspension

Chinese Pinyin: Lifuximing Ganhunxuanji

The main ingredient of this product is rifaximin. Its chemical name is 4-deoxy-4'-methylpyridine [1 ', 2'-1,2] -imidazo [5,4-cyclo] rifamycin SV .

Its structural formula is:

Molecular formula: C43H51N3O11

Molecular weight: 785.89

[Character]

This product is orange-red granules and powder.

[Pharmacology and Toxicology]

Pharmacological effects:

Rifaximin is a broad-spectrum enteric antibiotic. It is a semi-synthetic derivative of rifamycin SV. Rifaximin, like other rifamycin antibiotics, inhibits bacterial RNA synthesis by irreversibly binding to the b-subunit of bacterial DNA-dependent RNA polymerase, and ultimately inhibits bacterial protein synthesis. Since its binding to enzymes is irreversible, its activity is bactericidal activity against sensitive bacteria. Research on the antibacterial activity of rifaximin shows that this product has the same broad antibacterial spectrum as rifamycin, and it kills most Gram-positive and Gram-negative bacteria, including aerobic and anaerobic infections. effect.

Since rifaximin is not absorbed by the intestine when taken orally, it acts locally by killing pathogens in the intestine.

Toxicology research:

Repeated administration toxicity: Rats were orally administered 25mg / kg, 50mg / kg, and 100mg / kg of this product every day. After 180 consecutive days, they were well tolerated, except that the serum cholesterol of female mice showed a dose-dependent increase (possibly for intestinal bacteria). Group effect), no other abnormal changes.

Genotoxicity: No mutagenic effect of this product has been seen in vivo or in vitro.

Reproductive toxicity: Rats and rabbits given this product at 50mg / kg and 100mg / kg have no teratogenic effects and other reproductive toxicity.

Pharmacokinetics

Studies on pharmacokinetics in rats, dogs and humans have proven that this product is not absorbed orally (absorption less than 1%).

[Indications]

Intestinal infections caused by rifaximin-sensitive pathogens include acute and chronic intestinal infections, diarrheal syndrome, summer diarrhea, travel diarrhea, and enterocolitis.

Dosage

Adult Oral. 0.2g (2 bags) each time, 3 to 4 times a day.

Children 2-6 years old take orally. 0.1g (1 bag) each time, 4 times a day.

Children 6-12 years old take orally. 0.1-0.2g (1-2 bags) each time, 4 times a day.

Children over 12 years of age , the same dosage as adults.

The dosage and frequency can be adjusted according to the doctor's order. Except in the case of a doctor, each course should not exceed 7 days.

Adverse reactions

Nausea may develop in some patients (usually after the first dose), but symptoms may resolve quickly. Large doses of long-term medication may cause urticaria-like skin reactions in very few patients.

1. Headaches have been reported in the central nervous system.

2. Patients with hepatic encephalopathy of the metabolic / endocrine system may experience weight loss and slightly increase serum potassium and serum sodium concentrations after taking this drug.

3 Common symptoms of the gastrointestinal system are bloating, abdominal pain, nausea and vomiting. The incidence of the above symptoms is less than 1%.

4 Long-term use of large doses of skin may cause urticaria-like skin reactions in very few patients.

5. Other useful drugs may be reported after causing edema.

[Taboo]

The following patients are disabled:

1. People who are allergic to this medicine or rifamycin;

2. Intestinal obstruction;

3. Severe intestinal ulcerative lesions.

Precautions

1. Children should not take this medicine for more than 7 days.

2. It is recommended not to take tablets or capsules of this medicine for children under 6 years old.

3 When long-term high-dose medication or intestinal mucosa is damaged, a very small amount (less than 1%) is absorbed, resulting in pink urine.

4 Keep out of reach of children.

5. If microorganisms that are not sensitive to antibiotics are produced, treatment should be discontinued and other appropriate treatments taken.

6. Impact on driving and manipulating machines: unknown.

[Medication for pregnant and lactating women]

1. Effect of the drug on pregnancy: Animal tests have no teratogenic effect. However, the safety and effectiveness of medications for pregnant women are unclear. Therefore, pregnant women need to weigh the advantages and disadvantages of medication.

2. Effects of the drug on breastfeeding: Only a small amount of this drug is absorbed after oral administration, and the concentration in milk is extremely low. Lactating women can take this medicine with proper medical testing.

[Child medication]

Please refer to [Dosage and Administration] for children.

medicine interactions

Oral rifaximin is absorbed by the gastrointestinal tract in less than 1% of the oral dose, so it does not cause systemic problems caused by drug interactions.

[Drug overdose]

Tests have proven that there are no local or systemic adverse events at 1.6 g / day. Once taken in excess, gastric lavage should be used in conjunction with other appropriate treatments.

[Specification] Each contains rifaximin 0.1g.

[Storage] Sealed and stored in a cool and dry place.

[Validity] 36 months.

[ Packing ] Packed in aluminum plastic film, 0.1g × 12 bags / box.

[Approval number] National Medicine Standard H20040040

manufacturer

Company Name: Nanjing Chengong Pharmaceutical Co., Ltd.